Figure 5.
Figure 5. OS of patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone according to the presence of concurrent expression of MYC and BCL2 proteins (MYC+/BCL2+) or the presence of concurrent MYC and BCL2 translocations. Reprinted from Johnson et al73 with permission.

OS of patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone according to the presence of concurrent expression of MYC and BCL2 proteins (MYC+/BCL2+) or the presence of concurrent MYC and BCL2 translocations. Reprinted from Johnson et al73  with permission.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal